KurtROettelMD

Oncology • Black River Falls, WI

Medical Oncologist at Gundersen Health System

Join to view full profile

Dr. Oettel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Oettel's full profile

Already have an account?

Office
610 W Adams St
Black River Falls, WI 54615
Phone+1 608-775-2385

Fax+1 608-775-6627
Is this information wrong?

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1998 - 2001
University of Vermont Medical CenterResidency, Internal Medicine, 1995 - 1998
University of Wisconsin School of Medicine & Public HealthClass of 1995

Certifications & Licensure

WI State Medical License 1998 - 2025
IA State Medical License 2005 - 2024
MN State Medical License 2006 - 2024
VT State Medical License 1995 - 1998
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction Start of enrollment: 2009 Jan 21
Terminated
Phase 1, Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
Active, not recruiting
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Active, not recruiting
Phase 3
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Dec 14
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 18
Active, not recruiting
Phase 2
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
Recruiting
Phase 2, Phase 3
Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19
Recruiting
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Start of enrollment: 2023 Jul 13
Recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.
Brian Bourbeau, Gary H Lyman, Xiudong Jennifer Lei, Lee Jones, Jon Rosenthal, Mary May Kozlik, Kurt R Oettel, Alfred Tinger, Ray Page> ;JCO Oncology Practice. 2023 Jul 1
1 citations
A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Develop...
John Michael Varlotto, Zhuoxin Sun, Bonnie Ky, Jenica Upshaw, Thomas J Fitzgerald, Max Diehn, Christine Lovly, Chandra Belani, Kurt Oettel, Gregory Masters, Matthew Ha...> ;Clinical Lung Cancer. 2022 Nov 1
4 citations
A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
John M. Varlotto, Z. Sun, Bonnie Ky, Jenica N. Upshaw, Sharyn I. Katz, Thomas J. Fitzgerald, Heather A. Wakelee, Maximilian Diehn, David A. Mankoff, Christine Lovely, ...> ;The Oncologist. 2021 Jun 1
58 citations
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.
Nathan A. Pennell, Melissa S. Dillmon, Laura A. Levit, E. Allyn Moushey, Ajjai Alva, Sibel Blau, Timothy L. Cannon, Natalie R. Dickson, Maximilian Diehn, Mithat Gonen,...> ;Journal of Clinical Oncology. 2021 Jan 10
Benchmarks for Academic Oncology Faculty
Lowell B. Anthony, George F. Atweh, Ravi Bhatia, Lisa A. Carey, Jenny C. Chang, Martin J. Edelman, Philip W. Kantoff, Merry Jennifer Markham, Wells A. Messersmith, Edw...> ;JCO Oncology Practice. 2021 Mar 1
ASCO Voices 2020.
Daniel Rayson, Jose A. Bufill, Julia Close, Alice Cyusa, Kurt R. Oettel, Onyemaechi Okolo, Aparna Raj Parikh, Lidia Schapira> ;Journal of Clinical Oncology. 2020 Aug 9
13 citations
Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study
Joseph R. Mikhael, Judith Manola, Amylou C. Dueck, Suzanne R. Hayman, Kurt R. Oettel, Abraham S. Kanate, Sagar Lonial, S. Vincent Rajkumar> ;Blood Cancer Journal. 2018 Aug 29
58 citations
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a r...
Roy S. Herbst, Mary W. Redman, Edward S. Kim, Thomas J. Semrad, Lyudmila Bazhenova, Gregory A. Masters, Kurt R. Oettel, Perry Guaglianone, Christopher M. Reynolds, Ana...> ;The Lancet. Oncology. 2018 Jan 1
26 citations
Are We on the Same Page? Patient and Provider Perceptions About Exercise in Cancer Care: A Focus Group Study.
Agnes Smaradottir, Angela L. Smith, Andrew J. Borgert, Kurt R. Oettel> ;Journal of the National Comprehensive Cancer Network. 2017 May 1
29 citations
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
Tien Hoang, Toby C. Campbell, Chong Zhang, KyungMann Kim, Jill M. Kolesar, Kurt R. Oettel, Jules H. Blank, Emily Robinson, Harish Ahuja, Ron J. Kirschling, Peter H. Jo...> ;Investigational New Drugs. 2014 Feb 1
10 citations
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
Noelle K. LoConte, Kyle D. Holen, William R. Schelman, Daniel Mulkerin, Dustin A. Deming, Hilary R. Hernan, Anne M. Traynor, Timothy Goggins, David Groteluschen, Kurt ...> ;Investigational New Drugs. 2013 Aug 1
55 citations
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.
Anne M. Traynor, Tracey L. Weigel, Kurt R. Oettel, David T. Yang, Chong Zhang, KyungMann Kim, Ravi Salgia, Mari Iida, Toni M. Brand, Tien Hoang, Toby C. Campbell, Hila...> ;Lung Cancer. 2013 Jul 1
Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.
Jones MW, Zhang C, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling RJ, Johnson PH, Huie MS, Kolesar J, Wims MB, Hernan H, Campbell TC, Traynor AM, Hoang T> ;J. Clin. Oncol.. 2011-05-20
2 citations
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology ne...
Steven Attia, Anne M. Traynor, KyungMann Kim, Joseph Merchant, Tien Hoang, Harish Ahuja, Peter A. Beatty, Richard M. Hansen, Gregory A. Masters, Kurt R. Oettel, Gary R...> ;Journal of Thoracic Oncology. 2008 Sep 1
8 citations
Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test
Paul R. Hutson, Kurt R. Oettel, Jeffrey A. Douglas, Mark A. Ritter, Edward M. Messing, Mary Jane Staab, Dona Alberti, Dorthea Horvath, George Wilding> ;Cancer Chemotherapy and Pharmacology. 2008 Aug 1
2 citations
A morphealike skin condition caused by Borrelia burgdorferi in an immunocompromised patient.
Jeffrey S. Sartin, Kurt R. Oettel> ;Mayo Clinic Proceedings. 2006 Sep 1
9 citations
Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma
Michael S. Huie, Kurt R. Oettel, Lynn Van Ummersen, Mann Kim Kyung, Yulin Zhang, Mary Jane Staab, Dottie Horvath, Rebecca Marnocha, Jeffrey A. Douglas, Amy Drezen, Don...> ;Investigational New Drugs. 2006 May 1
6 citations
Phase I/II Study of Gemcitabine and Exisulind as Second-Line Therapy in Patients with Advanced Non–small Cell Lung Cancer
Tien Hoang, KyungMann Kim, Joseph Merchant, Anne M. Traynor, James McGovern, Kurt R. Oettel, Fredrico A. Sanchez, Harish Ahuja, Thomas A. Hensing, Martha M. Larson, Jo...> ;Journal of Thoracic Oncology. 2006 Mar 1
Phase I/II study of exisulind and gemcitabine in patients with recurrent advanced non-small cell lung cancer (NSCLC).
Hoang T, Kim K, Merchant J, Traynor AM, Ahuja HG, Masters GA, McGovern JD, Oettel KR, Sanchez FA, Schiller JH> ;J. Clin. Oncol.. 2004-07-15
Phase I/II study of exisulind (E) and vinorelbine (V) in elderly patients with advanced non-small cell lung cancer (NSCLC).
Traynor AM, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Schiller JH> ;J. Clin. Oncol.. 2004-07-15
41 citations
Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.
Glenn Liu, Kurt R. Oettel, Howard H. Bailey, Lynn Van Ummersen, Kendra D. Tutsch, Mary Jane Staab, Dorothea Horvath, Dona Alberti, Rhoda Z. Arzoomanian, Hamied Rezazad...> ;Investigational New Drugs. 2003 Aug 1
52 citations
Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer
Glenn Liu, Kurt R. Oettel, Gregory H. Ripple, Mary Jane Staab, Dorothea Horvath, Dona Alberti, Rhoda Z. Arzoomanian, Rebecca Marnocha, Reginald C. Bruskewitz, Richard ...> ;Clinical Cancer Research. 2002 Sep 1
43 citations
Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient
Kurt R. Oettel, Osvaldo H. Wesly, Mark R. Albertini, Jacquelyn A. Hank, Othon Lliopolis, Jeffrey A. Sosman, Karl V. Voelkerding, Shi Qi Wu, Steven S. Clark, Paul M. So...> ;Blood. 1994 Jun 1
5 citations
Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy.
Mark R. Albertini, Oettel Kr, Gilda Weil-Hillman, Mary J. Lindstrom, Schell K, Jacquelyn A. Hank, Paul M. Sondel> ;Journal of Biological Response Modifiers. 1990 Oct 1
66 citations
Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determ...
Jeffrey A. Sosman, Kurt R. Oettel, Stephen D Smith, Jacquelyn A. Hank, Paul Fisch, Paul M. Sondel> ;Blood. 1990 May 15
Join now to see all

Press Mentions

Wisconsin Cancer Survivor Writes a BookNovember 22nd, 2020
ASCO Voices 2020August 9th, 2020
Gundersen Receives Grant to Fund Cancer Research Clinical TrialsAugust 16th, 2019
Join now to see all